AveXis Inc. | $AVXS Stock | Shares Spike On Positive Top Line Results For AVXS-101 Despite Q4 Loss

0
705
AveXis Inc.

AveXis Inc. (NASDAQ: AVXS)

 

 

AveXis Inc. (AVXS), a clinical-stage gene therapy company yesterday reported top line results from its phase 1 trial of AVXS-101 in spinal muscular atrophy SMA type 1. AveXis also reported their fourth quarter and full year 2016 financial results. AveXis reported a fourth quarter loss of $25.4 million. AveXis reported fourth quarter earnings of a loss of $0.92 per share which fell short of analyst expectations of a loss of $0.77 per share.    

 

AveXis Inc. CEO’s Comments

“The completion of our Phase 1 clinical study of AVXS-101, the first ever gene therapy studied for the treatment of SMA Type 1, is an exciting and eagerly awaited milestone, and we are quite pleased with these data,” said Sean Nolan, President and Chief Executive Officer of AveXis. “The past few months have been productive for AveXis, and we look forward to continuing the momentum with several upcoming corporate catalysts, including the planned Type B CMC meeting with the FDA, as well as ongoing collaborative discussions with regulatory authorities in the United States and Europe to explore the most expeditious pathways for marketing approval of AVXS-101.”  Globe Newswire

 

AVXS Technical Analysis

AveXis Inc.

AVXS opened trading yesterday at $74.46 which was down from the previous day’s trading close of $74.88. Shares closed trading yesterday at $72.78 and spiked up after market to $81.50, equivalent to a 12% increase from the closing price. Taking a look at the daily chart we can see that we are in un-chartered territory as with the spike up, AVXS is now trading at all time highs.

Taking a closer look at the daily chart we can see that before the spike up AVXS had already been in an overall upward trend dating back to January 3rd when it traded at $47.26. AVXS has a float of 15.97 million shares and traded 1.31 times the normal daily trading volume on Thursday.

For trading purposes, I would like to see AVXS open trading on Friday above $78.50 and if it does I would be looking to take a long position at the bell. My stop loss would be $0.50 from my entry position fearing anything more than that and the stock would start to fill in the gap up.

 

Company Profile

AveXis Inc., a clinical-stage gene therapy company, engages in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.

The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases. It has strategic collaboration and license agreements with Nationwide Children’s Hospital;

The Research Institute at Nationwide Children’s Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014. AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.  Yahoo Finance

 

 

IMAGE CREDIT

SHARE
Previous articleAlarm.com Holdings, Inc. | $ALRM Stock | Shares Climb Up On Better Than Expected Q4 Earnings
Next articleOraSure Technologies, Inc. | $OSUR Stock | Shares Shoot Up On Announcement Of Joining S&P Small Cap 600
You can reach us at our TickerTV Office via support@ticker.tv or by phone (917) 720-3537. Legal Disclaimer – This is not meant to be a recommendation to buy or to sell securities nor an offer to buy or sell securities. Before selling or buying any stock or other investment you should consult with a qualified broker or other financial professional. The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author has no business relationship with any company whose stock is mentioned in this article nor is receiving compensation from any of the companies mentioned.

LEAVE A REPLY